Midostaurin

Major

Midostaurin Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Midostaurin Enzalutamide Xtandi Decreased midostaurin exposure Details Midostaurin Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Midostaurin Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Midostaurin Fluconazole Diflucan Increased sensitive CYP3A4 substrates exposure Details Midostaurin Fosphenytoin Cerebyx Decreased midostaurin exposure Details Midostaurin Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Midostaurin Givinostat Duvyzat Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Midostaurin Glyburide DiaBeta® Increased OATP1B1 substrate exposure Details Midostaurin Grazoprevir Increased OATP1B1 substrate exposure Details Midostaurin Idelalisib Zydelig Increased midostaurin exposure Details Midostaurin Imatinib Gleevec Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Midostaurin Indinavir Increased midostaurin exposure Details Midostaurin Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Itraconazole Sporanox Increased midostaurin exposure Details Midostaurin Ketoconazole Extina Increased midostaurin exposure Details Midostaurin Lanreotide Altered exposure to CYP3A4 substrate Details Midostaurin Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Midostaurin Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Midostaurin Letermovir Prevymis Increased OATP1B1 substrate exposure Details Midostaurin Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Midostaurin Lopinavir Increased midostaurin exposure Details Midostaurin Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Midostaurin Lumacaftor Decreased midostaurin exposure Details Midostaurin Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Midostaurin Methadone Diskets Reduced methadone exposure and an increased risk of opioid withdrawal symptoms Details Midostaurin Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Midostaurin Mitotane Lysodren Decreased midostaurin exposure Details Midostaurin Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Midostaurin Nefazodone Increased midostaurin exposure Details Midostaurin Nelfinavir Viracept Increased midostaurin exposure Details Midostaurin Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Midostaurin Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Midostaurin Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Midostaurin Ozanimod Increased BCRP substrate exposure Details Midostaurin Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Midostaurin Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Midostaurin Phenytoin Dilantin Decreased midostaurin exposure Details Midostaurin Pitavastatin Livalo Increased OATP1B1 substrate exposure Details Midostaurin Posaconazole Noxafil Increased posaconazole exposure and increased midostaurin exposure Details